Protagenic Therapeutics, Inc. - PTIX Net earnings per share (EPS TTM)

The annual EPS TTM delta demonstrates the financial trajectory of Protagenic Therapeutics (PTIX), which integrates ESG principles and ethics into the synthesis of peptides for depression. The value 59.30 represents the current metric. The development of the PT00114 drug is supported by a steady stream of volunteers under FDA supervision, while the neurobiology team is retained by the opportunity for scientific freedom and equity stakes in the company.
Protagenic Therapeutics Inc. - analytical breakdowns and key metrics (PTIX)

This indicator serves as a key tool for assessing the growth rate of net earnings per share. By analyzing the percentage change in EPS over a rolling year, an investor can gauge the speed of financial performance transformation. The calculation is based on comparing the current TTM figure with the same period from the previous year. For Protagenic Therapeutics (PTIX), such volatility reflects the high risks associated with the early stages of neurodrug development. Competition for capital and patents makes this trend critical for assessing the business's viability.